These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 28739263)

  • 1. Pilot Randomized Controlled Trial of Titrated Subcutaneous Ketamine in Older Patients with Treatment-Resistant Depression.
    George D; Gálvez V; Martin D; Kumar D; Leyden J; Hadzi-Pavlovic D; Harper S; Brodaty H; Glue P; Taylor R; Mitchell PB; Loo CK
    Am J Geriatr Psychiatry; 2017 Nov; 25(11):1199-1209. PubMed ID: 28739263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single, Repeated, and Maintenance Ketamine Infusions for Treatment-Resistant Depression: A Randomized Controlled Trial.
    Phillips JL; Norris S; Talbot J; Birmingham M; Hatchard T; Ortiz A; Owoeye O; Batten LA; Blier P
    Am J Psychiatry; 2019 May; 176(5):401-409. PubMed ID: 30922101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Placebo-controlled pilot trial testing dose titration and intravenous, intramuscular and subcutaneous routes for ketamine in depression.
    Loo CK; Gálvez V; O'Keefe E; Mitchell PB; Hadzi-Pavlovic D; Leyden J; Harper S; Somogyi AA; Lai R; Weickert CS; Glue P
    Acta Psychiatr Scand; 2016 Jul; 134(1):48-56. PubMed ID: 27028832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pilot dose-response trial of i.v. ketamine in treatment-resistant depression.
    Lai R; Katalinic N; Glue P; Somogyi AA; Mitchell PB; Leyden J; Harper S; Loo CK
    World J Biol Psychiatry; 2014 Sep; 15(7):579-84. PubMed ID: 24910102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy, Safety, and Durability of Repeated Ketamine Infusions for Comorbid Posttraumatic Stress Disorder and Treatment-Resistant Depression.
    Albott CS; Lim KO; Forbes MK; Erbes C; Tye SJ; Grabowski JG; Thuras P; Batres-Y-Carr TM; Wels J; Shiroma PR
    J Clin Psychiatry; 2018; 79(3):. PubMed ID: 29727073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repeated intranasal ketamine for treatment-resistant depression - the way to go? Results from a pilot randomised controlled trial.
    Gálvez V; Li A; Huggins C; Glue P; Martin D; Somogyi AA; Alonzo A; Rodgers A; Mitchell PB; Loo CK
    J Psychopharmacol; 2018 Apr; 32(4):397-407. PubMed ID: 29542371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial.
    Loo C; Glozier N; Barton D; Baune BT; Mills NT; Fitzgerald P; Glue P; Sarma S; Galvez-Ortiz V; Hadzi-Pavlovic D; Alonzo A; Dong V; Martin D; Nikolin S; Mitchell PB; Berk M; Carter G; Hackett M; Leyden J; Hood S; Somogyi AA; Lapidus K; Stratton E; Gainsford K; Garg D; Thornton NLR; Fourrier C; Richardson K; Rozakis D; Scaria A; Mihalopoulos C; Chatterton ML; McDonald WM; Boyce P; Holtzheimer PE; Kozel FA; Riva-Posse P; Rodgers A
    Br J Psychiatry; 2023 Dec; 223(6):533-541. PubMed ID: 38108319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid and Sustained Reductions in Current Suicidal Ideation Following Repeated Doses of Intravenous Ketamine: Secondary Analysis of an Open-Label Study.
    Ionescu DF; Swee MB; Pavone KJ; Taylor N; Akeju O; Baer L; Nyer M; Cassano P; Mischoulon D; Alpert JE; Brown EN; Nock MK; Fava M; Cusin C
    J Clin Psychiatry; 2016 Jun; 77(6):e719-25. PubMed ID: 27232360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ketamine safety and tolerability in clinical trials for treatment-resistant depression.
    Wan LB; Levitch CF; Perez AM; Brallier JW; Iosifescu DV; Chang LC; Foulkes A; Mathew SJ; Charney DS; Murrough JW
    J Clin Psychiatry; 2015 Mar; 76(3):247-52. PubMed ID: 25271445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized controlled pilot study of daily intravenous ketamine over three days for treatment-resistant depression.
    Pattanaseri K; Lortrakul J; Jaisin K; Srifuengfung M; Sa-Nguanpanich N; Viravan N; Pariwatcharakul P; Makarasara W; Ratta-Apha W
    BMC Psychiatry; 2024 Jul; 24(1):512. PubMed ID: 39026266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ketamine augmentation for outpatients with treatment-resistant depression: Preliminary evidence for two-step intravenous dose escalation.
    Cusin C; Ionescu DF; Pavone KJ; Akeju O; Cassano P; Taylor N; Eikermann M; Durham K; Swee MB; Chang T; Dording C; Soskin D; Kelley J; Mischoulon D; Brown EN; Fava M
    Aust N Z J Psychiatry; 2017 Jan; 51(1):55-64. PubMed ID: 26893373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increase in PAS-induced neuroplasticity after a treatment course of intranasal ketamine for depression. Report of three cases from a placebo-controlled trial.
    Gálvez V; Nikolin S; Ho KA; Alonzo A; Somogyi AA; Loo CK
    Compr Psychiatry; 2017 Feb; 73():31-34. PubMed ID: 27886522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial.
    Daly EJ; Trivedi MH; Janik A; Li H; Zhang Y; Li X; Lane R; Lim P; Duca AR; Hough D; Thase ME; Zajecka J; Winokur A; Divacka I; Fagiolini A; Cubala WJ; Bitter I; Blier P; Shelton RC; Molero P; Manji H; Drevets WC; Singh JB
    JAMA Psychiatry; 2019 Sep; 76(9):893-903. PubMed ID: 31166571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
    Feder A; Parides MK; Murrough JW; Perez AM; Morgan JE; Saxena S; Kirkwood K; Aan Het Rot M; Lapidus KA; Wan LB; Iosifescu D; Charney DS
    JAMA Psychiatry; 2014 Jun; 71(6):681-8. PubMed ID: 24740528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Repeated oral ketamine for out-patient treatment of resistant depression: randomised, double-blind, placebo-controlled, proof-of-concept study.
    Domany Y; Bleich-Cohen M; Tarrasch R; Meidan R; Litvak-Lazar O; Stoppleman N; Schreiber S; Bloch M; Hendler T; Sharon H
    Br J Psychiatry; 2019 Jan; 214(1):20-26. PubMed ID: 30246667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ninety-six hour ketamine infusion with co-administered clonidine for treatment-resistant depression: A pilot randomised controlled trial.
    Lenze EJ; Farber NB; Kharasch E; Schweiger J; Yingling M; Olney J; Newcomer JW
    World J Biol Psychiatry; 2016 Apr; 17(3):230-8. PubMed ID: 26919405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subcutaneous Midazolam with and without Ketamine for Sedation In Children Undergoing Dental Treatment: A Pilot Study.
    Flores-Castillo D; Martínez-Rider R; Ruiz-Rodríguez S; Garrocho-Rangel A; Lara-Guevara J; Pozos-Guillén A
    J Clin Pediatr Dent; 2015; 39(4):382-6. PubMed ID: 26161612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Augmentation of response and remission to serial intravenous subanesthetic ketamine in treatment resistant depression.
    Shiroma PR; Johns B; Kuskowski M; Wels J; Thuras P; Albott CS; Lim KO
    J Affect Disord; 2014 Feb; 155():123-9. PubMed ID: 24268616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Electrophysiological correlates and predictors of the antidepressant response to repeated ketamine infusions in treatment-resistant depression.
    de la Salle S; Phillips JL; Blier P; Knott V
    Prog Neuropsychopharmacol Biol Psychiatry; 2022 Apr; 115():110507. PubMed ID: 34971723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Repeat-dose ketamine augmentation for treatment-resistant depression with chronic suicidal ideation: A randomized, double blind, placebo controlled trial.
    Ionescu DF; Bentley KH; Eikermann M; Taylor N; Akeju O; Swee MB; Pavone KJ; Petrie SR; Dording C; Mischoulon D; Alpert JE; Brown EN; Baer L; Nock MK; Fava M; Cusin C
    J Affect Disord; 2019 Jan; 243():516-524. PubMed ID: 30286416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.